Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up

J. Wilding*, C. Bailey, U. Rigney, B. Blak, M. Kok, C. Emmas

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Aims: To investigate prescribing patterns and effect of dapagliflozin among individuals with T2DM using UK primary care data. Methods: Adult patients with T2DM initiating dapagliflozin treatment were identified from the Clinical Practice Research Datalink. Changes in HbA1c, body weight and systolic blood pressure were assessed in subgroups defined by glucose lowering treatment at baseline and compliance with the Summary of Product Characteristics. Logistic regression examined the association of baseline characteristics with achievement of target HbA1c (≤53. mmol/mol) and weight reduction (by ≥3.0%). Results: Among 5828 eligible individuals, HbA1c was reduced from a baseline mean of 80.0. mmol/mol (SD 17.6) by -12.8 (95% CI -13.8, -11.8). mmol/mol at >12-24 months. The corresponding value for weight reduction (baseline mean 101.7. kg) was -5.0 (-5.4, -4.5). kg, and for systolic blood pressure reduction (baseline mean 134.1. mmHg) was -3.1 (-4.0, -2.2) mmHg. Lower baseline HbA1c values (<69; 69-85 versus ≥86. mmol/mol) were positively associated with achievement of target HbA1c <53. mmol/mol. Conclusions: Treatment with dapagliflozin in T2DM was associated with reductions in HbA1c, weight and systolic blood pressure over time periods up to 2 years. Changes in these parameters were consistent with those reported in RCTs.

Original languageEnglish
Pages (from-to)437-444
Number of pages8
JournalPrimary Care Diabetes
Volume11
Issue number5
Early online date2 Jun 2017
DOIs
Publication statusPublished - 1 Oct 2017

Fingerprint

Type 2 Diabetes Mellitus
Primary Health Care
Blood Pressure
Weights and Measures
Weight Loss
Therapeutics
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Logistic Models
Body Weight
Glucose
Research

Cite this

Wilding, J. ; Bailey, C. ; Rigney, U. ; Blak, B. ; Kok, M. ; Emmas, C. / Dapagliflozin therapy for type 2 diabetes in primary care : changes in HbA1c, weight and blood pressure over 2 years follow-up. In: Primary Care Diabetes. 2017 ; Vol. 11, No. 5. pp. 437-444.
@article{4c0bc57259734f04bf27537b0da6a045,
title = "Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up",
abstract = "Aims: To investigate prescribing patterns and effect of dapagliflozin among individuals with T2DM using UK primary care data. Methods: Adult patients with T2DM initiating dapagliflozin treatment were identified from the Clinical Practice Research Datalink. Changes in HbA1c, body weight and systolic blood pressure were assessed in subgroups defined by glucose lowering treatment at baseline and compliance with the Summary of Product Characteristics. Logistic regression examined the association of baseline characteristics with achievement of target HbA1c (≤53. mmol/mol) and weight reduction (by ≥3.0{\%}). Results: Among 5828 eligible individuals, HbA1c was reduced from a baseline mean of 80.0. mmol/mol (SD 17.6) by -12.8 (95{\%} CI -13.8, -11.8). mmol/mol at >12-24 months. The corresponding value for weight reduction (baseline mean 101.7. kg) was -5.0 (-5.4, -4.5). kg, and for systolic blood pressure reduction (baseline mean 134.1. mmHg) was -3.1 (-4.0, -2.2) mmHg. Lower baseline HbA1c values (<69; 69-85 versus ≥86. mmol/mol) were positively associated with achievement of target HbA1c <53. mmol/mol. Conclusions: Treatment with dapagliflozin in T2DM was associated with reductions in HbA1c, weight and systolic blood pressure over time periods up to 2 years. Changes in these parameters were consistent with those reported in RCTs.",
author = "J. Wilding and C. Bailey and U. Rigney and B. Blak and M. Kok and C. Emmas",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.pcd.2017.04.004",
language = "English",
volume = "11",
pages = "437--444",
number = "5",

}

Dapagliflozin therapy for type 2 diabetes in primary care : changes in HbA1c, weight and blood pressure over 2 years follow-up. / Wilding, J.; Bailey, C.; Rigney, U.; Blak, B.; Kok, M.; Emmas, C.

In: Primary Care Diabetes, Vol. 11, No. 5, 01.10.2017, p. 437-444.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dapagliflozin therapy for type 2 diabetes in primary care

T2 - changes in HbA1c, weight and blood pressure over 2 years follow-up

AU - Wilding, J.

AU - Bailey, C.

AU - Rigney, U.

AU - Blak, B.

AU - Kok, M.

AU - Emmas, C.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Aims: To investigate prescribing patterns and effect of dapagliflozin among individuals with T2DM using UK primary care data. Methods: Adult patients with T2DM initiating dapagliflozin treatment were identified from the Clinical Practice Research Datalink. Changes in HbA1c, body weight and systolic blood pressure were assessed in subgroups defined by glucose lowering treatment at baseline and compliance with the Summary of Product Characteristics. Logistic regression examined the association of baseline characteristics with achievement of target HbA1c (≤53. mmol/mol) and weight reduction (by ≥3.0%). Results: Among 5828 eligible individuals, HbA1c was reduced from a baseline mean of 80.0. mmol/mol (SD 17.6) by -12.8 (95% CI -13.8, -11.8). mmol/mol at >12-24 months. The corresponding value for weight reduction (baseline mean 101.7. kg) was -5.0 (-5.4, -4.5). kg, and for systolic blood pressure reduction (baseline mean 134.1. mmHg) was -3.1 (-4.0, -2.2) mmHg. Lower baseline HbA1c values (<69; 69-85 versus ≥86. mmol/mol) were positively associated with achievement of target HbA1c <53. mmol/mol. Conclusions: Treatment with dapagliflozin in T2DM was associated with reductions in HbA1c, weight and systolic blood pressure over time periods up to 2 years. Changes in these parameters were consistent with those reported in RCTs.

AB - Aims: To investigate prescribing patterns and effect of dapagliflozin among individuals with T2DM using UK primary care data. Methods: Adult patients with T2DM initiating dapagliflozin treatment were identified from the Clinical Practice Research Datalink. Changes in HbA1c, body weight and systolic blood pressure were assessed in subgroups defined by glucose lowering treatment at baseline and compliance with the Summary of Product Characteristics. Logistic regression examined the association of baseline characteristics with achievement of target HbA1c (≤53. mmol/mol) and weight reduction (by ≥3.0%). Results: Among 5828 eligible individuals, HbA1c was reduced from a baseline mean of 80.0. mmol/mol (SD 17.6) by -12.8 (95% CI -13.8, -11.8). mmol/mol at >12-24 months. The corresponding value for weight reduction (baseline mean 101.7. kg) was -5.0 (-5.4, -4.5). kg, and for systolic blood pressure reduction (baseline mean 134.1. mmHg) was -3.1 (-4.0, -2.2) mmHg. Lower baseline HbA1c values (<69; 69-85 versus ≥86. mmol/mol) were positively associated with achievement of target HbA1c <53. mmol/mol. Conclusions: Treatment with dapagliflozin in T2DM was associated with reductions in HbA1c, weight and systolic blood pressure over time periods up to 2 years. Changes in these parameters were consistent with those reported in RCTs.

UR - http://www.scopus.com/inward/record.url?scp=85020106750&partnerID=8YFLogxK

UR - https://www.sciencedirect.com/science/article/pii/S1751991817300724?via%3Dihub

U2 - 10.1016/j.pcd.2017.04.004

DO - 10.1016/j.pcd.2017.04.004

M3 - Article

AN - SCOPUS:85020106750

VL - 11

SP - 437

EP - 444

IS - 5

ER -